CD39 expression on immune cells predicts methotrexate response in rheumatoid arthritis patients.

Autor: Boral B; Department of Immunology, Adana Health Practice and Research Center, University of Health Sciences, Adana, Turkiye., Tuncer İ; Department of Immunology, Prof. Dr. Cemil Taşcıoğlu City Hospital, University of Health Sciences, İstanbul, Turkiye., Kibar F; Department of Medical Microbiology, Faculty of Medicine, Çukurova University, Adana, Turkiye., Çetiner S; Department of Immunology, Faculty of Medicine, Çukurova University, Adana, Turkiye., Badak SÖ; Division of Rheumatology, Department of Internal Medicine, Adana City Training and Research Hospital, Adana Turkiye., Salman E; Department of Immunology, Ankara City Hospital, University of Health Sciences, Ankara, Turkiye., Koç E; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Çukurova University, Adana, Turkiye., Erken E; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Çukurova University, Adana, Turkiye., Yaman A; Department of Immunology, Adana Health Practice and Research Center, University of Health Sciences, Adana, Turkiye.
Jazyk: angličtina
Zdroj: Turkish journal of medical sciences [Turk J Med Sci] 2023 Sep 09; Vol. 53 (5), pp. 1075-1083. Date of Electronic Publication: 2023 Sep 09 (Print Publication: 2023).
DOI: 10.55730/1300-0144.5672
Abstrakt: Background/aim: Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting mostly small joints, such as hand and foot joints symmetrically with irreversible joint destruction. In this study, the relationship between CD39 expression and the treatment response of RA patients was examined to investigate its potential as a biomarker that demonstrates treatment response.
Materials and Methods: This study included 77 RA patients and 40 healthy controls (HC). The RA patients were divided into 2 groups based on their response to RA treatment, those with a good response to methotrexate (MTX) monotherapy and those with an inadequate response based on the American College of Rheumatology and the European League Against Rheumatism response criteria. Various immunological parameters and Disease Activity Score in 28 Joints (DAS28) were examined between the groups using the Student's t-test.
Results: The monocytic myeloid-derived suppressor cell (M-MDSC) percentage was higher in the RA patient group versus the HC group. The CD39 expression in the T lymphocytes were higher in patients that responded well to the MTX compared to those showing inadequate response. Additionally, s negative correlation was found between the DAS28 and CD39 in the T cells.
Conclusion: The results showed that the improvement in treatment response to the therapy in RA patients could be because of the enhancement in the CD39/adenosine (ADO) pathway. Therefore, therapies targeting the CD39/ADO pathway in T cells may improve RA treatments.
Competing Interests: Conflict of interest: There are no conflicts of interest.
(© TÜBİTAK.)
Databáze: MEDLINE
Externí odkaz: